RESUMO
Continuous renal replacement therapy (CRRT) has become an effective multiple organ support therapy instead of single renal replacement as initially expected, and it is widely used in intensive care unit (ICU). After the outbreak of coronavirus disease 2019 (COVID-19), a series of expert recommendation or consensus have been developed to diagnose and treat the disease, including CRRT in acute kidney injury (AKI) and hyper inflammatory response. However, CRRT in COVID-19 is extraordinarily different from regular one due to different pathophysiology and infectious clinical scenarios. Accordingly, the paper aims to elaborate the similarities and differences between CRRT in COVID-19 and routine treatment in terms of safety and accessibility, indications and timing, clinical operation, anticoagulation, fluid management, prevention and control of infectious diseases, etc.
RESUMO
Colorectal cancer is one of the most common cancer.Despite the survival rate of patients with metastatic disease has been raised due to the combination therapy of chemotherapy and opetation,few longterm survivors exist.The detection of circulating tumor cells (CTC) is an evolving technology whose significance has been discussed for more than a century.The advence of modem technology has allowed for more reliable detection of CTCs,and recent studies have provided compelling evidence that CTCs can predict clinical outcome in metastatic colorectal cancer (mCRC).In this review,we will discuss the evidence for CTC significance,with particular focus on detection methods,novel markers,and clinical outcomes in CRC,and future challenges in testing them as a means to individualize the therapy of mCRC patients.